Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 11/20 | 0.36 |
| ▸ | FNTB | P49356 | 11/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477908 | 0.96 | MME (0.41) | MMEENPEPFNTAFNTBPGGT1B | |
| SCHEMBL30477906 | 0.96 | MME (0.41) | MMEENPEPFNTAFNTBPGGT1B | |
| SCHEMBL30477916 | 0.96 | MME (0.41) | MMEENPEPFNTAFNTBPGGT1B | |
| SCHEMBL30477910 | 0.96 | MME (0.41) | MMEENPEPFNTAFNTBPGGT1B | |
| SCHEMBL30477922 | 0.96 | MME (0.41) | MMEENPEPFNTAFNTBPGGT1B | |
| SCHEMBL30477918 | 0.96 | MME (0.41) | MMEENPEPFNTAFNTBPGGT1B | |
| SCHEMBL29749072 | 0.93 | FNTA (0.38) | MMEFNTAFNTBPGGT1B | |
| SCHEMBL27906687 | 0.93 | FNTA (0.38) | MMEFNTAFNTBPGGT1B | |
| SCHEMBL29381057 | 0.93 | FNTA (0.38) | MMEFNTAFNTBPGGT1B | |
| SCHEMBL29378004 | 0.92 | MME (0.37) | MMEFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623088-A1 | BIOPRODUCTION OF GLYCOLIC ACID FROM GLYOXAL | BIOC3 (FR) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110642-A1 | BIOPRODUCTION OF GLYCOLIC ACID FROM GLYOXAL | BIOC3 (FR) | 2024-05-30 | — | — | WO | claimed |
| EP-4375379-A1 | BIOPRODUCTION OF GLYCOLIC ACID FROM GLYOXAL | BIOC3 (FR) | 2024-05-29 | — | — | EP | claimed |
| EP-4739120-A1 | FOAMABLE DAIRY PRODUCTS | Novozymes A/S (DK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739123-A1 | METHODS FOR OBTAINING PLANT-BASED READY-TO-DRINK COFFEE OR TEA BEVERAGES | Novozymes A/S (DK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739141-A1 | METHOD FOR OBTAINING A DAIRY ALTERNATIVE FOOD PRODUCT WITH IMPROVED FOAMING | Novozymes A/S (DK) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026089568-A1 | NOVEL PEPTIDE AND COMPOSITION FOR IMPROVING SKIN COMPRISING SAME | (주)아모레퍼시픽 | 2026-04-30 | — | — | WO | disclosed |
| US-20260096575-A1 | ENZYMATIC METHOD OF PRODUCING PLANT PROTEIN EXTRACT | NOVOZYMES A/S (DK) | 2026-04-09 | — | — | US | disclosed |
| US-20260070949-A1 | POLYPEPTIDES HAVING DEAMIDASE INHIBITOR ACTIVITY | NOVOZYMES A/S (DK) | 2026-03-12 | — | — | US | disclosed |
| US-12565666-B2 | Methods and compositions for modulating a genome | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-12559534-B2 | Modified IL-2 proteins, peg conjugates, and uses thereof | CSPC Megalith Biopharmaceutical Co., Ltd. (CN) | 2026-02-24 | — | — | US | disclosed |
| CN-114901308-A | Compositions and methods for treating cancer using anti-HER 2 antibody drug conjugates | 石药集团巨石生物制药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11377492-B2 | NKp46 binding agents | INNATE PHARMA (FR) | 2022-07-05 | — | — | US | disclosed |
| WO-2022116714-A1 | COMPOUND AND MEDICAL USE THEREOF FOR NOVEL CORONAVIRUS PNEUMONIA | 中国药科大学 | 2022-06-09 | — | — | WO | disclosed |
| EP-3154574-B1 | HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS | CSPC MEGALITH BIOPHARMACEUTICAL CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| CN-112920136-B | Compound and medical application thereof in novel coronavirus pneumonia | 中国药科大学 | 2022-05-03 | — | — | CN | disclosed |
| EP-3986917-A1 | MODIFIED IL-2 PROTEINS, PEG CONJUGATES, AND USES THEREOF | CSPC Megalith Biopharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| US-11285128-B2 | Homogenous antibody drug conjugates via enzymatic methods | CSPC Megalith Biopharmaceutical Co., Ltd. (CN) | 2022-03-29 | — | — | US | disclosed |
| CN-114245802-A | Modified IL-2 proteins, PEG conjugates and uses thereof | 石药集团巨石生物制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220056432-A1 | TRANSGLUTAMINASE NANOFLOWERS | INDIAN INSTITUTE OF TECHNOLOGY DELHI (IN) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377492-B2 | NKp46 binding agents | LY96, CD74, CD2BP2 | MME 719/4885ENPEP 558/4885FNTA 2226/4885 |
| US-11285128-B2 | Homogenous antibody drug conjugates via enzymatic methods | TGM2, FCGR1A, TGM3 | MME 320/4885ENPEP 11/4885FNTA 471/4885 |
| US-20260096575-A1 | ENZYMATIC METHOD OF PRODUCING PLANT PROTEIN EXTRACT | ASNS, GLUL, PEPD | MME 236/4885ENPEP 19/4885FNTA 595/4885 |
| US-20260070949-A1 | POLYPEPTIDES HAVING DEAMIDASE INHIBITOR ACTIVITY | FBL, DPEP1, DUT | MME 53/4885ENPEP 67/4885FNTA 755/4885 |
| US-12559534-B2 | Modified IL-2 proteins, peg conjugates, and uses thereof | IL2, IL2RA, ILF2 | MME 4227/4885ENPEP 807/4885FNTA 1624/4885 |
| US-12565666-B2 | Methods and compositions for modulating a genome | RPRD2, ERN2, TPR | MME 1137/4885ENPEP 1624/4885FNTA 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.